Abstract 307P
Background
Lacrimal gland is an exocrine secretory gland located at the upper temporal fossa of the orbit. It is part of the tear-forming apparatus that constitutes an important orbital structure. However, data available about tumors possibly originating in this site are scarce. In this study, we aimed to spotlight on this rare type of malignancy using the using data from American National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program.
Methods
We used SEER*Stat version 8.3.4, Microsoft Excel, as well as SPSS IBM SPSS Statistics for Windows, Version 21.0. In SEER*Stat, we used the (Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying)) database. We included SEER 18 cases that were diagnosed after 2003 (2004+) in which the primary site was identified as (C69.5 – Lacrimal gland). Only cases with malignant behavior, known age, and those in the Research Database were included.
Results
A total of 491 cases were identified with a median age of 63. Females represented the majority of the analyzed cohort (n = 263, 53.6%). Lacrimal gland tumors were most common among the white race (n = 376, 76.6%). Age-adjusted Incidence rate was 0.6 per 1,000,000 with a median survival of 41 months, while 5-year relative survival was 88.4% (CI: 81.9% - 92.6%). The most common pathology of studied cases was Non-Hodgkin lymphoma (n = 254, 51.7%) (Table).Table:
307P Different pathological subtypes for lacrimal gland tumours
Pathological Subtype | N. | % |
---|---|---|
NHL-Mature B-Cell Lymphomas | 254 | 51.7 % |
Squamous Cell Neoplasms | 71 | 14.5 % |
Adenomas &Adenocarcinomas | 64 | 13.0 % |
Malignant Lymphomas, NOS Or Diffuse | 32 | 6.5 % |
Mucoepidermoid Neoplasms | 17 | 3.5 % |
Epithelial Neoplasms, NOS | 10 | 2.0 % |
Nevi Melanomas | 8 | 1.6 % |
Ductal & Lobular Neoplasms | 7 | 1.4 % |
Lymphoid Leukemias (C42.1) | 6 | 1.2 % |
Transitional Cell Papillomas & Carcinomas | 4 | 0.8 % |
Complex Mixed & Stromal Neoplasms | 4 | 0.8 % |
Myomatous Neoplasms | 3 | 0.6 % |
Basal Cell Neoplasms | 2 | 0.4 % |
Complex Epithelial Neoplasms | 2 | 0.4 % |
Plasma Cell Tumors | 2 | 0.4 % |
Unspecified Neoplasms | 1 | 0.2 % |
Cystic, Mucinous & Serous Neoplasms | 1 | 0.2 % |
Fibromatous Neoplasms | 1 | 0.2 % |
Hodgkin Lymphomas | 1 | 0.2 % |
Nhl-Mature T & Nk-Cell Lymphomas | 1 | 0.2 % |
Conclusions
Lacrimal gland tumors are extremely rare with incidence rate of 0.6 per million. These tumors are more likely to occur in old age, females, white race. 5-years relative survival is 88.4% with a median survival of 41 months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Impact of chemotherapy and radiotherapy on tissue expander or implant removal in breast cancer patients
Presenter: Sungmi Jung
Session: Poster display session
Resources:
Abstract
5P - Long-term prognostic effect of hormone receptor subtype on breast cancer
Presenter: Ki-tae Hwang
Session: Poster display session
Resources:
Abstract
6P - Effect of apparent diffusion coefficient in predicting pathologic responses in patients with breast cancer treated with neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel
Presenter: Yutaka Mizuno
Session: Poster display session
Resources:
Abstract
7P - Current diagnostic strategy for mammographic microcalcification without specific ultrasound abnormality
Presenter: Naoki Sato
Session: Poster display session
Resources:
Abstract
8P - Comparison of standard uptake value of 18F-FDG-PET-CT with tumour-infiltrating lymphocytes in breast cancer ≥1cm
Presenter: Soeun Park
Session: Poster display session
Resources:
Abstract
10P - Prognosis and effect of adjuvant treatment in small, node(-), HER2(+) breast cancer
Presenter: Seungtaek Lim
Session: Poster display session
Resources:
Abstract
11P - The prognosis of rare histopathologic subtype of breast cancer
Presenter: Soo Youn Bae
Session: Poster display session
Resources:
Abstract
12P - Daily collection of physical activity via smartphone application and smart band for development of distress screening tools in breast cancer survivors: A feasibility study
Presenter: Yungil Shin
Session: Poster display session
Resources:
Abstract
13P - Breast cancer distribution in East Azerbaijan, Iran: Results of population-based cancer registry
Presenter: Shima Pashaei
Session: Poster display session
Resources:
Abstract
14P - Validation of the optimum timing of assessment of tumour infiltrating lymphocytes during preoperative chemotherapy for breast cancer
Presenter: Shinichiro Kashiwagi
Session: Poster display session
Resources:
Abstract